PhRMA taps Tauzin for top post

The Pharmaceutical Research and Manufacturers of America (PhRMA) confirmed Billy Tauzin to succeed Alan Holmer as president and chief executive.
Tauzin, a Louisiana Republican retiring after 12 terms in the House of Representatives, was long rumored to be the PhRMA's choice for the job, but not without controversy. Tauzin's previous role as chairman of the House Energy and Commerce Committee, which oversees the pharmaceutical industry, and his active involvement in crafting the Medicare drug benefit law have drawn criticism from Democrats and government watchdog groups.
PhRMA chairman Miles White called Tauzin "a leader that embodies action," in a statement.
Tauzin will take up his new post on Jan. 3.
You must be a registered member of MMM to post a comment.
close

Next Article in Careers

Email Newsletters


What does going "beyond the pill" actually mean? At MM&M's recent inaugural spring conference, audience members heard from real-world companies that are managing the organizational, technological, and promotional challenges inherent in this transition, such as partnering with health neophytes, harnessing technologies that allow deeper engagement with patients, and adopting a new commercial mindset to serve, not sell. Download here.


A wave of more effective anti-cancer drugs has set the oncology world on fire with enthusiasm. While many hail this as a new era, an equally vocal faction questions the money spent for the value gained. This medical and commercial trend report for marketers of anti-cancer modalities touches on many of the latest shifts that have expedited product launches and otherwise impacted promotion and reimbursement of these drugs. Click here.